Kronos Bio, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation
Stock-based compensation expense, excluding restructuring
Depreciation and amortization
Net accretion on available-for-sale securities
Change in accrued interest on available-for-sale securities
Change in fair value of convertible notes payable
Debt issuance costs on convertible notes payable
Acquired in-process research and development
Stock-based compensation expense
Noncash lease expense
Change in operating lease right-of-use assets
Impairment of operating lease right of use asset and leasehold improvements
Loss from write down of held for sale assets
Non-cash impairment of long-lived assets and restructuring

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other noncurrent assets
Accounts payable
Accrued expenses
Right-of-use operating assets and liabilities, net
Other liabilities
Accrued expenses and other current liabilities
Current and noncurrent operating lease liabilities
Deferred revenue
Current portion of other liabilities and other noncurrent liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Purchase of marketable securities
Maturities of marketable securities
Proceeds from sale of marketable securities
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from initial public offering, net of commission and issuance costs
Proceeds from issuance of convertible notes, net of issuance costs
Principal payments on finance lease
Proceeds from issuance of common stock upon exercise of stock options
Proceeds from issuance of common stock under the employee stock purchase plan
Proceeds from issuance of preferred stock, net of financing fees
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosures of non-cash activities:
Common stock issued on conversion of convertible preferred stock
Common stock issued on conversion of convertible notes payable
Property and equipment additions included in accounts payable and accrued expenses
Reduction of right-of-use asset due to modification
Right-of-use asset obtained in exchange for operating lease liability
Property and equipment obtained in exchange for finance lease liability
Issuance of convertible preferred stock upon conversion of convertible notes

Cash and cash equivalents at end of period
Restricted cash at end of period

Comments